<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960826</url>
  </required_header>
  <id_info>
    <org_study_id>2020_11</org_study_id>
    <secondary_id>2020-A02380-39</secondary_id>
    <nct_id>NCT04960826</nct_id>
  </id_info>
  <brief_title>Study of an Environmental Risk Factor in Crohn's Disease</brief_title>
  <acronym>EVICTION</acronym>
  <official_title>dEoxyniValenol as Risk Factor for Inflammatory Bowel Diseases: Human detoxifiCaTion and Impact On intestiNal Microbiota and Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Agency, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory bowel disease (IBD) are lifelong chronic diseases affecting the gastrointestinal&#xD;
      tract. The precise etiology and the different actors participating to the pathophysiological&#xD;
      process leading to the disease development are still not well understood. A complex&#xD;
      interaction between genetics, gut microbiota and environmental factors is thought to trigger&#xD;
      the inappropriate mucosal immune response observed in IBD patients. We hypothesize that DON&#xD;
      might be an environmental risk factor for IBD.The focus on the human relevance of the gut&#xD;
      effects of DON by studying its exposure, metabolism and adverse effects in health and disease&#xD;
      focusing on IBD patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of Deoxynivalenol and its conjugated metabolites by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS).</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Crohn's disease patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non IBD patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Group 1: patients with ileocolic Crohn's disease requiring surgery&#xD;
&#xD;
          -  Group 2: Patients requiring ileal and / or colonic surgery for a reason other than&#xD;
             Crohn's disease or ulcerative colitis (for example, cancer, polyp or diverticulum).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group 1: patients with ileocolic Crohn's disease requiring surgery&#xD;
&#xD;
          -  Group 2: Patients requiring ileal and / or colonic surgery for a reason other than&#xD;
             Crohn's disease or ulcerative colitis (for example, cancer, polyp or diverticulum).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vegetarian or vegan patients, celiac disease, gluten sensitivity, eating disorders,&#xD;
             people with a particular diet or eating behavior or suffering from obesity or anorexia&#xD;
&#xD;
          -  Surgical history: patient having undergone intestinal resection&#xD;
&#xD;
          -  Current treatments: patient receiving antibiotic or probiotic treatment within 6 weeks&#xD;
             prior to inclusion / patient having taken topical treatment (suppositories or enema of&#xD;
             5ASA or corticosteroids) within 6 weeks prior to inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe ZERBIB, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe ZERBIB, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.zerbib@chru-lille.fr</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

